Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D08ZKN
|
||||
Former ID |
DCL000002
|
||||
Drug Name |
PG-530742
|
||||
Synonyms |
PG 116800; PG 530742; PGE 530742; PGE 7113313; PG-116800
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Osteoarthritis; Myocardial infarction [ICD9: 410, 715; ICD10:I21, I22, M15-M19, M47] | Discontinued in Phase 2 | [536172] | ||
Company |
Pharmagenesis
|
||||
Structure |
Download2D MOL |
||||
Formula |
C23H25N3O7S
|
||||
Canonical SMILES |
COC1=CC=C(C=C1)C(=O)NC2=CC=C(C=C2)S(=O)(=O)NC(C#CCN3CCO<br />CC3)C(=O)O
|
||||
InChI |
1S/C23H25N3O7S/c1-32-19-8-4-17(5-9-19)22(27)24-18-6-10-20(11-7-18)34(30,31)25-21(23(28)29)3-2-12-26-13-15-33-16-14-26/h4-11,21,25H,12-16H2,1H3,(H,24,27)(H,28,29)
|
||||
InChIKey |
WJDDDFUBTYNDPP-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 291533-11-4
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
Target and Pathway | |||||
Target(s) | Stromelysin-1 | Target Info | Inhibitor | [528049], [536172] | |
NetPath Pathway | IL1 Signaling Pathway | ||||
IL4 Signaling Pathway | |||||
PANTHER Pathway | Plasminogen activating cascade | ||||
CCKR signaling map ST | |||||
References | |||||
Ref 528049 | Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006 Mar;6(3):227-39. | ||||
Ref 536172 | Selective matrix metalloproteinase inhibition attenuates progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure. Am J Physiol Heart Circ Physiol. 2006 Jun;290(6):H2522-7. Epub 2006 Jan 20. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.